ArticleOncology letters2025
Pancreatic metastasis from cervical cancer: A case report and literature review.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer metastasis to the pancreas is rare, and the clinical manifestations are variable and contingent upon the location of the metastasis. Consequently, certain patients may be overlooked due to the absence of overt clinical symptoms. Nevertheless, there is no universally accepted treatment protocol for such patients. The present report describes a case of a 64-year-old woman with stage IIIB cervical squamous cell carcinoma (International Federation of Gynecology and Obstetrics 2009) who received definitive chemoradiation in March 2018 [intensity modulated radiation therapy (IMRT) + weekly paclitaxel + brachytherapy]. After 6 years, pancreatic metastasis was confirmed by MRI/PET-CT and endoscopic ultrasonography-guided fine-needle aspiration biopsy. Between January and May 2024, the patient underwent six cycles of paclitaxel/carboplatin/bevacizumab/programmed cell death protein 1 inhibitor therapy followed by IMRT (45 Gy with 55 Gy boost). Post-treatment imaging revealed a partial response (lesion reduction from 45×30 mm to 32×20 mm). As of November 2024, the latest data indicated that the patient was disease-free on pembrolizumab maintenance. Furthermore, a systematic review of 14 related cases described in previous studies to analyze the characteristics of metastatic pancreatic cancer (mPC) is presented. In total, 14 publications were identified for systematic review. Among these patients, 7 had squamous cell carcinoma. The median age of the patients at the time of initial diagnosis was 49.8 years, and the mean interval between the identification of the primary tumor and metastasis was 46 months. Several clinical manifestations were observed depending on the site of metastasis. Endoscopic ultrasonography-guided fine-needle aspiration was revealed as one of the most effective methods for diagnosing mPC. In conclusion, there is currently no consensus regarding subsequent treatment plans. Pancreatic metastases originating from cervical cancer are infrequent and necessitate careful consideration along with individualized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.